Alvotech Q2 FY26 earnings call ALVO

Alvotech successfully resubmitted its U.S. Biologics License Applications (BLAs) for AVT-05 (Symphony biosimilar), AVT-06 (EYLEA biosimilar), and the dual products Prolia/XGEVA biosimilar in June 2026. These resubmissions followed a comprehensive improvement program at the company's manufacturing facility in Reykjavik, which addressed FDA observations from mid-2025. In July 2026, the FDA formally closed a routine GMP surveillance inspection of the facility with a Voluntary Action Indicated (VAI) classification, confirming the facility's approved status and the effectiveness of corrective actions. These regulatory advancements are expected to pave the way for FDA approvals in the fourth quarter of 2026.

The company's commercial portfolio has expanded significantly, with five biosimilars now contributing to product revenue: Humira (AVT02), Stelara (AVT04), Symphony (AVT05), EYLEA (AVT06), and Prolia/XGEVA biosimilar. AVT02 maintains the #2 biosimilar position in the U.S. adalimumab market, which now sees over 60% biosimilar penetration. AVT04 has achieved approximately 60% penetration in the U.S. ustekinumab market. AVT05 and AVT06 have launched across more than 10 European markets and Japan, with AVT05 showing encouraging early momentum in Germany and Spain, achieving over 15% market share in Europe.

Alvotech continues to build one of the industry's largest internally developed biosimilar pipelines, with over 30 candidates. Key programs advancing include biosimilars to KEYTRUDA (co-developed with Dr. Reddy's), ENTYVIO (AVT16 and AVT80), and EYLEA HD (AVT29). European marketing authorization applications for both ENTYVIO biosimilars have been validated, and the FDA has accepted the BLA for AVT16, with AVT80's U.S. BLA submission anticipated soon. The ALVO-I-HD clinical study for AVT29 is progressing, targeting a U.S. regulatory submission in 2028, positioning it as a potential first-wave EYLEA HD biosimilar.

The company successfully completed an equity financing in June 2026, raising approximately $165 million in gross proceeds and diversifying its shareholder base. This was complemented by securing an additional term loan facility of up to $75 million, bringing total new financing to $240 million. These funds enhance financial flexibility, supporting continued investment in the pipeline, preparation for additional product launches, global commercialization, and manufacturing requirements. Cash on hand at the end of June was $143 million, with expectations for healthy deleveraging in 2027.

While Alvotech primarily operates through a business-to-business model with commercial partners globally, the company is exploring opportunities for more direct participation in the U.S. market. This includes potentially commercializing selected pipeline products directly. This strategic evolution aims to optimize market access and value capture for its growing portfolio of biosimilars, leveraging its integrated development and manufacturing platform.